<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312454</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-038</org_study_id>
    <nct_id>NCT01312454</nct_id>
  </id_info>
  <brief_title>Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C</brief_title>
  <official_title>A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety and efficacy of AL-59412C injected
      intravitreally relative to Vehicle.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Management decision
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum intraocular (IOP) reduction from baseline up to 24 hours post-injection</measure>
    <time_frame>Time to event, up to 24 hours post-injection</time_frame>
    <description>IOP was measured by Goldman applanation tonometry at protocol-specified timepoints, up to 24 hours post-injection.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>AL-59412C Concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-59412C injectable solution, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-59412C Concentration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-59412C injectable solution, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost injectable solution, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AL-59412C Vehicle, single intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-59412C injectable solution</intervention_name>
    <description>Concentration 1 and Concentration 2</description>
    <arm_group_label>AL-59412C Concentration 1</arm_group_label>
    <arm_group_label>AL-59412C Concentration 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost injectable solution</intervention_name>
    <arm_group_label>Travoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-59412C Vehicle</intervention_name>
    <description>Inactive ingredients used as placebo</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension.

          -  Retinal pathology (eg, retinal degeneration), anterior ischemic optic neuropathy, or
             vascular occlusion resulting in poor vision in the study eye.

          -  Able to discontinue all intraocular-lowering (IOP) medications according to the
             minimum washout period, based upon the class of medication.

          -  Mean washed out IOP ≥ 24 millimeters mercury (mmHg) to ≤ 36 mmHg at 8 AM in the study
             eye on two separate Eligibility Visits.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Lens/corneal/vitreal opacity preventing adequate posterior segment visualization of
             the study eye.

          -  Current or recent (within 30 days) use of any drug that may prolong the QT interval.

          -  Poor vision resulting from advanced glaucoma in the study eye.

          -  Intraocular surgery within the past 6 months in the study eye.

          -  Ocular laser surgery within the past 3 months in the study eye.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Landry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <disposition_first_submitted>September 26, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 26, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 25, 2013</disposition_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intravitreal injection</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

